Organic Synthesis at the Service of Biology and Medicine

为生物学和医学服务的有机合成

• 批准号: 10704547
• 负责人: Ouathek Ouerfelli
• 金额: $ 23.3万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-17 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10704547
• 关键词: Binding; Biology; Cancer Detection; Chemicals; Chemistry; Collaborations; Communities; Core Facility; Detection; Development; Disease; FDA approved; Funding; Head; Human Resources; Knowledge; Leadership; Malignant Neoplasms; Medicine; Memorial Sloan-Kettering Cancer Center; NCI Center for Cancer Research; Organic Synthesis; Pharmaceutical Chemistry; Pharmaceutical Preparations; Prevention; Research; Research Personnel; Services; Specialist; Therapeutic Agents; cancer biomarkers; chemical synthesis; collaborative environment; preclinical study; stem; success; synergism; tool

Dr. Ouathek Ouerfelli directs the organic synthesis core facility (OSCF) at Memorial Sloan Kettering Cancer Center (MSK) since 2004. He is committed to provide chemistry services for the MSK research community and the development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The core head possesses more than 25 years of chemistry collaborations and service of MSK investigators, more than half of whom are NCI grantees. Along these lines, he contributed to major endeavors by eminent colleagues who are NCI grantees such as Dr. Charles Sawyers (R01 CA155169) which led to an FDA approved drug, Dr. Scott Lowe (R01 CA155169) with several projects that are showing promise, as well as Dr. Craig Thompson (RO1 CA168802) for the development of a new cancer markers among others. He maintains a state-of-the art facility with expert professional personnel in chemical synthesis. OSCF has now the capability to support medicinal chemistry efforts to evolve agents in support of MSK investigators. Under his leadership, the core has greatly facilitated preclinical studies at the Center.

Ouathek Ouerfelli博士在纪念Sloan指导有机合成核心设施（OSCF） 自2004年以来，Kettering Cancer Center（MSK）。他致力于为 MSK研究界以及开发新工具和治疗剂 癌症检测，预防和治疗。核心负责人拥有超过25年的 MSK调查人员的化学合作和服务，其中一半以上是NCI 受赠人。沿着这些界限，他为著名同事的重大努力做出了贡献 NCI授予者，例如Charles Sawyers（R01 CA155169），导致FDA批准的药物， 斯科特·洛（Scott Lowe）博士（R01 CA155169），有几个显示出希望的项目，以及博士 Craig Thompson（RO1 CA168802）用于开发新的癌症标志物。 他维护着最先进的设施，并拥有专业的专业专业人选化学合成。 OSCF现在有能力支持药物化学努力以发展支持代理 MSK调查人员。在他的领导下，核心在 中心。

项目成果

Mechanistic details of the actinobacterial lyase-catalyzed degradation reaction of 2-hydroxyisobutyryl-CoA.

放线菌裂解酶催化 2-羟基异丁酰-CoA 降解反应的机制细节。

• DOI: 10.1016/j.jbc.2021.101522
• 发表时间: 2022-01
• 期刊: The Journal of biological chemistry
• 作者: Zahn M;König G;Pham HVC;Seroka B;Lazny R;Yang G;Ouerfelli O;Lotowski Z;Rohwerder T
• 通讯作者: Rohwerder T